Payment overview · 2025
General Payments
$144.02
7 reported records · 6 companies
Healthcare provider profile · identity verified
Christopher Steele Kinne, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DANBURY, CT · NPI 1275021610
Verified facts
What the public records show
CMS Open Payments records show Christopher Steele Kinne, MD received $144.02 in general payments during 2025 across 7 reported records.
Viatris Specialty LLC accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $34.36 | 23.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.95 | 19.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.81 | 16.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.01 | 15.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.74 | 14.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.15 | 10.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $144.02 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $34.36 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.95 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.95 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 210 | 62 |
| Gabapentin | Gabapentin | 207 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 190 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 180 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 178 | 68 |
| Lisinopril | Lisinopril | 175 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 53 |
| Tramadol Hcl | Tramadol Hcl | 155 | 40 |
| Losartan Potassium | Losartan Potassium | 127 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 121 | 51 |
| Alprazolam | Alprazolam | 111 | 25 |
| Pregabalin | Pregabalin | 105 | 26 |
| Lorazepam | Lorazepam | 103 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 27 |
| Furosemide | Furosemide | 101 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 40 |
| Oxycodone Hcl | Oxycodone Hcl | 84 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 25 |
| Metformin Hcl | Metformin Hcl | 80 | 27 |
| Sertraline Hcl | Sertraline Hcl | 76 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 27 |
| Jardiance | Empagliflozin | 67 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 22 |
| Warfarin Sodium | Warfarin Sodium | 67 | 19 |
| Trazodone Hcl | Trazodone Hcl | 64 | 21 |
| Baclofen | Baclofen | 60 | 15 |
| Simvastatin | Simvastatin | 60 | 24 |
| Diazepam | Diazepam | 59 | 12 |
| Eliquis | Apixaban | 56 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 27 |
| Carvedilol | Carvedilol | 52 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 24 |
| Buspirone Hcl | Buspirone Hcl | 50 | 11 |
| Potassium Chloride | Potassium Chloride | 49 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 18 |
| Clonazepam | Clonazepam | 46 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 17 |
| Meloxicam | Meloxicam | 43 | 15 |
| Metformin Hcl Er | Metformin Hcl | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 14 |
| Montelukast Sodium | Montelukast Sodium | 42 | 17 |
| Ezetimibe | Ezetimibe | 39 | 15 |
| Bupropion Xl | Bupropion Hcl | 38 | 11 |
| Methocarbamol | Methocarbamol | 37 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | 14 |
| Famotidine | Famotidine | 36 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 35 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Prednisone | Prednisone | 32 | 19 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Belsomra | Suvorexant | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 20 |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 16 |
| Naproxen | Naproxen | 21 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 12 |
| Brilinta | Ticagrelor | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Ssd | Silver Sulfadiazine | 14 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Sucralfate | Sucralfate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Dayvigo | Lemborexant | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Triazolam | Triazolam | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $144.02 · 7 records | Viatris Specialty LLC | EVENITY, FARXIGA, Kerendia, LEQVIO, NURTEC ODT, YUPELRI, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error